科内抄読会: 自己免疫性疾患におけるCD19 CAR T療法 (長期フォローを含めて)

投稿した先生からのメッセージ

概要

本スライドの対象者

参考文献

• Müller F, Taubmann J, Bucci L et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024 Feb 22;390(8):687-700. PMID38381673.

• CAR-T療法

• Akatsuka Y, CAR-T細胞療法の基礎と今後の臨床展開, Japanese Journal of Transfusion and Cell Therapy, Vol. 65. No. 6 65（6） ： 851―857, 2019

• von Büdingen HC, Palanichamy A, Lehmann-Horn K et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73(3-4):238-246. PMID 25824054

• 大西 康, CAR-T細胞療法の基礎知識, 日本造血・免疫細胞療法学会雑誌, 2023, 12 巻, 3 号, p. 148-156

• Antaa slide “最近話題のCAR-T療法ってなあに?

• Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022 Oct;28(10):2124-2132. PMID 36109639

• Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019 Mar 6;11(482):eaav1648. PMID 30842314

• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 Feb 20;292(8):403-7. doi: 10.1056/NEJM197502202920807. PMID: 1089199.

• van den Hoogen F, Khanna D, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov;65(11):2737-47. PMID24122180

• Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017 May;69(5):898-910. PMID28382787

• Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465-72. PMID20391500

• Valentini G, Iudici M, Walker UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017 Jan;76(1):270-276. PMID: 27621285.

• Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. PMID: 28516167.

• 日本皮膚科学会 全身性強皮症 診断基準・重症度分類・診療ガイドライン委員会 日本皮膚科学会ガイドライン「全身性強皮症 診断基準・重症度分類・診療ガイドライン」

• Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. PMID: 30592986.

• Mougiakakos D, Krönke G, Völkl S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021 Aug 5;385(6):567-569. PMID: 34347960.

• Müller F, Boeltz S, Knitza J, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023 Mar 11;401(10379):815-818. PMID: 36930673.

• Taubmann J, Knitza J, Müller F, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. PMID: 37432378

• Bergmann C, Müller F, Distler JHW, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023 Aug;82(8):1117-1120. PMID: 37147112.

• BD Biosciences https://www.bdbiosciences.com/ja-jp/learn/research/immunology/b-cells#Overview

• Abcam https://www.abcam.co.jp/primary-antibodies/b-cells-basic-immunophenotyping-2

• Kubo S, Nakayamada S, Yoshikawa M, et al. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis Rheumatol. 2017 Oct;69(10):2029-2037. PMID: 28605137.

• Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006 Nov;54(11):3612-22 PMID: 17075806.

• Illei GG, Yarboro CH, Kuroiwa T, et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford). 2007 Jun;46(6):952-6. PMID: 17317716.

• Adams EM, Pucino F, Yarboro C, et al. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol. 1999 Feb;26(2):352-60. PMID: 9972969.

• Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 Feb 8;12(1):868. PMID: 33558511

• Hamieh M, Dobrin A, Cabriolu A et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019 Apr;568(7750):112-116. PMID: 30918399.

• https://www.ritsumei.ac.jp/~mnakayam/research.html

• https://www.yodosha.co.jp/jikkenigaku/book/9784758125734/2948.html

• Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024 May 30:ard-2024-225785. PMID: 38777376.

• Zhang W, Feng J, Cinquina A et al. Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. Stem Cell Rev Rep. 2021 Dec;17(6):2120-2123. PMID: 34458965.